Gómez-Limón L, Hernández-Pineda AH, Castellón-Lomelí CI, Cruz-Rodríguez JA

Idioma: Español
Referencias bibliográficas: 34
Paginas: 378-387
Archivo PDF: 427.17 Kb.

RESUMEN

La reacción inmunológica que provoca la tormenta de citocinas en la infección por el nuevo coronavirus facilita la aparición de daño microvascular, endotelial y celular directo, lo que lleva a un estado protrombótico y eventos de tromboembolismo a diferentes aparatos y sistemas como complicación. De ahí la necesidad de proporcionar adecuada terapia profiláctica o manejo anticoagulante en tiempo y dosificación adecuados a estos pacientes, así como un estudio de la coagulación y hemostasia individualizado. En este documento se pretende resumir de manera práctica la evidencia publicada hasta el momento y otorgar una visión más amplia de los fenómenos fisiopatológicos que suceden en este estado hiperinflamatorio que mucho nos ha enseñado desde su llegada.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ten VS1, Pinsky DJ. Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 2002: 242-50. DOI: 10.1097/00075198- 200206000-00008.

2. Baumann L. COVID-19 and VTE/anticoagulation: frequently asked questions. American Society of Haematology. 2020. https://www.hematology.org/covid-19/covid-19-and-vteanticoagulation.

3. Klok FA, Krulp M, van der Meer N, Arbous M, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147. doi: 10.1016/j.thromres.2020.04.013.

4. Song J, Wang G, Zhang W, Zhang Y, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Military Medical Research 2020. https://doi.org/10.1186/s40779-020-00247-7.

5. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 1421-1424. DOI: 10.1111/jth.14830.

6. Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc 2020; 22 (2): 95-97.

7. Middeldorp S, Coppens M, Haaps TF, Foppen M, Vlaar AP, Muller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020; 1995-2002. doi: 10.1111/jth.14888.

8. Kollias A. Thrombooembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action. Br J Haemtaol 2020 doi: 10.1111/bjh.16727.

9. Sociedad Española de Trombosis y Hemostasia. Recomendaciones de tromboprofilaxis y tratamiento antitrombótico en pacientes con covid-19. Sociedad Española de Trombosis y Hemostasia, 2020.

10. Griffin P, Neal S. Bethesda, Manual de Hematología Clínica. 4th ed. Wolters Luwer, 2018; 20: 419-457.

11. Litao Z. Dimer D levels on admission to predict in-hospital mortality in patients with Covid-1. Int Soc Thrombosis Haemostasis 2020. doi: 10.1111/jth.14859.

12. Spyropoulos AC, Lipardi C, Xu J, Peluso C, et al. Modified IMPROVE VTE risk score and elevated d-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH Open 2020: 59-65. doi: 10.1055/s-0040-1705137.

13. Massachusets General Hospital. Aspectos hematológicos durante el COVID-19. The General Hospital Corporation. 2020.

14. Piera-Carbonell A, Frías-Vargas M, García-Vallejo O, García-Lerín A, Cabrera-Ferriols MA, Peiró-Morant J, Carrasco-Carrasco, et al. COVID-19 y tromboprofilaxis: recomendaciones para nuestra práctica clínica en Atención Primaria. Semergen 2020; 46 (7): 479-486. DOI: 10.1016/j. semerg.2020.07.007.

15. Thachil J, Tang N, Gando S, Falanga A, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020. https://doi. org/10.1111/jth.14810.

16. Vivas D, Roldán V, Esteve-Pastor MA, Roldán I, Tello- Montoliu A, et al. Recomendaciones sobre el tratamiento antitrombotico durante la ´ pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología Rev Esp Cardiol 2020. doi: https://doi.org/10.1016/j.recesp.2020.04.006

17. Li J, Li Y, Yang B, Wang H, Li L. Low-molecular-weight heparin treatment for acute lung injury / acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2018; 11: 414-422. doi: 10.1111/1751- 2980.12815.

18. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. http://dx.doi. org/10.1001/jamainternmed.2020.0994.

19. Fox S, Akmatbekov A, Harbert JL, Li G, Brown JW, Heide R. Pulmonary and cardiac pathology in Covid-19: The First autopsy series from New Orleans. medRxiv 2020. https:// doi.org/10.1101/2020.04.06.20050575.

20. Bagot C, Miles B, Chalmers G, et al. GGC Medicines Guidelines Prevention of thrombosis in COVID 19 in adult inpatient not receiving renal replacement therapy (RRT) on critical care wards. 2020.

21. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094-1099. http://dx.doi. org/10.1111/jth.14817.

22. López-Reyesa R, Osculloa G, Jiménez D, Canoc I, García- Ortega A. Thrombotic risk and Covid-19: Review of current evidence for a better diagnostic and therapeutic approach. Arch Bronconeumol 2020. DOI: 10.1016/j. arbres.2020.07.033.

23. Barrett C. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment. International Society on Thrombosis and Haemostasis 2020. https://doi.org/10.1111/jth.14860.

24. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9: 727-732. doi: 10.1080/22221751.2020.1746199.

25. NHS Covid Treatment Group. Thromboprofylaxis and anticogagulatcion in COVID 29 infection. Imperial College Hetalthcare. 2020.

26. Retter A. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID- 19. Prof Beverley Hunt OBE 2020.

27. Taylor FB. ISTH Criteria for Disseminated Intravascular Coagulation (DIC). International Society on Thrombosis and Haemostasis. 2004.

28. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood 2018: 845-854. https://doi. org/10.1182/blood-2017-10-804096.

29. Roffi M, Oechslin E. Kardiologische Indikationen zur oralen Antikoagulation. Cardiac indications for oral anticoagulation. Praxis (Bern 1994) 2004; 93 (38): 1549-1555. DOI: 10.1024/0369-8394.93.38.1549.

30. Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A. Switch from oral anticoagulants to parenteral heparin in SARSCoV- 2 hospitalized patients. Int Emerg Med 2020; 1-5. DOI: 10.1007/s11739-020-02331-1.

31. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Disponible en: https://www.covid19treatmentguidelines. nih.gov/.

32. Rattanawong P, Shen W, Masri H, Sorajja D, et al. Guidance on short-term management of atrial fibrillation in coronavirus disease 2019. J Am Heart Assoc 2020; 9: e017529. doi: 10.1161/JAHA.120.017529.

33. Bikdeli B. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020: 14. doi: 10.1016/j. jacc.2020.04.031.

34. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines. nih.gov/.